[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647156":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":25,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":25,"enrollmentInfo":49,"targetDuration":25,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":69,"whyStopped":25,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":25},{"fullName":5,"class":6},"Wah Medical college , POF hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Verapamil group","ACTIVE_COMPARATOR","Participants received intravenous verapamil, initial dose 5 mg over 2 minutes; if target heart rate (\\\u003C110 bpm) not achieved within 15 minutes, an additional 5 mg IV dose given, to a cumulative maximum of 10 mg.",[13],"Drug: Verapamil Hydrochloride",{"label":15,"type":10,"description":16,"interventionNames":17},"Metoprolol group","Participants received intravenous metoprolol tartrate, initial dose 5 mg over 2 minutes; if target heart rate (\\\u003C110 bpm) not achieved within 5 minutes, up to two additional 5 mg IV doses given at 5-minute intervals, to a cumulative maximum of 15 mg.",[18],"Drug: Metoprolol tartrate",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Verapamil Hydrochloride","Intravenous verapamil administered as an initial 5 mg dose over 2 minutes, with an additional 5 mg dose permitted after 15 minutes if target heart rate not achieved, up to a cumulative maximum of 10 mg.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Metoprolol tartrate","Intravenous metoprolol tartrate administered as an initial 5 mg dose over 2 minutes, with up to two additional 5 mg doses at 5-minute intervals if target heart rate not achieved, up to a cumulative maximum of 15 mg.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Muhammad Ali Javed, MBBS","CONTACT","+923295718202","ajaved123886@gmail.com",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Muhammad Ali Javed","Clinical Professor","100647156","phase-4-comparing-two-heart-medicines-for-fast-irregular-heartbeat-atrial-fibrillation-100647156",false,"NCT07706075","Comparing Two Heart Medicines for Fast, Irregular Heartbeat (Atrial Fibrillation)","Verapamil Versus Metoprolol for Rate Control in Hemodynamically Stable Atrial Fibrillation With Rapid Ventricular Response","Inclusion Criteria:\n\n* Adult patients aged 18 years and above presenting to the Emergency Department\n* Confirmed diagnosis of atrial fibrillation with rapid ventricular response (heart rate ≥110 bpm) on 12-lead ECG\n* Hemodynamically stable at the time of enrollment (systolic blood pressure ≥90 mmHg, no shock, no acute pulmonary edema)\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Hemodynamic instability, cardiogenic shock, or acute decompensated heart failure\n* Known pre-excitation syndrome (e.g., Wolff-Parkinson-White syndrome) on baseline ECG\n* Severe left ventricular systolic dysfunction (ejection fraction less than 30%) as determined by echocardiography\n* Known hypersensitivity or contraindication to verapamil or metoprolol\n* Patients already taking rate control agents (beta-blockers, calcium channel blockers, or digoxin) in the last 24 hours\n* Major bradycardia (heart rate less than 50 bpm) or AV block (second or third degree) on baseline ECG\n* Active bronchospasm or severe obstruction of pulmonary disease\n* Severe hepatic impairment (Child-Pugh Class C) or acute renal failure (eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²)\n* Pregnancy or breastfeeding\n* Inability to give informed consent","ALL","18 Years",{"count":50,"type":51},120,"ESTIMATED","INTERVENTIONAL",[54],"PHASE4","The goal of this clinical trial is to learn whether intravenous verapamil or intravenous metoprolol controls heart rate more effectively in adult patients who arrive at the emergency department with atrial fibrillation and a fast heart rate (rapid ventricular response), but who are otherwise medically stable. Atrial fibrillation with a rapid heart rate is a common emergency, and doctors currently choose between these two standard medicines based on personal preference rather than strong local evidence, since there is limited research on this comparison in Pakistani patients.\n\nThe main questions this study aims to answer are:\n\nDoes a higher proportion of patients reach a target heart rate of less than 110 beats per minute within 30 minutes with verapamil compared to metoprolol? Which medicine controls the heart rate faster, on average? Are there differences in side effects (such as low blood pressure, slow heart rate, or breathing problems) between the two medicines? Researchers will compare a group of patients receiving verapamil to a group receiving metoprolol to see if one medicine controls the heart rate faster and more safely than the other.\n\nParticipants will:\n\n1. Receive either verapamil or metoprolol through an IV, with the dose given according to standard protocols\n2. Have their heart rate, blood pressure, and oxygen levels monitored continuously for 30 minutes after the medicine is given\n3. Be observed for any side effects during this monitoring period Both medicines used in this study are already standard, guideline-recommended treatments for this condition, so participation will not change or delay the medical care patients would normally receive.",[57,58],"Atrial Fibrillation (AF)","Atrial Fibrillation With Rapid Ventricular Response",[60,61,62,63,64,65,66,67,68],"atrial fibrillation","Rapid ventricular Response","Rate Control","Verapamil","Metoprolol","Calcium Channel Blockers","Beta Blockers","Cardiac Arrythmia","Hemodynamically unstable","NOT_YET_RECRUITING","2026-07-30",{"date":72,"type":73},"2026-08-03","ACTUAL",{"date":75,"type":51},"2027-01-01",{"date":77,"type":51},"2027-08-01",{"name":38,"class":6}]